Selected article for: "acute respiratory syndrome and global network"
Author: Guan, Wenyi; Lan, Wendong; Zhang, Jing; Zhao, Shan; Ou, Junxian; Wu, Xiaowei; Yan, Yuqian; Wu, Jianguo; Zhang, Qiwei
Title: COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine
  • Cord-id: essgkkv1
  • Document date: 2020_9_30
    • ID: essgkkv1
    Snippet: The World Health Organization (WHO) has declared coronavirus disease 2019 (COVID-19) is the first pandemic caused by coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, there is no effective anti-SARS-CoV-2 drug approved worldwide for treatment of patients with COVID-19. Therapeutic options in response to the COVID-19 outbreak are urgently needed. To facilitate the better and faster development of therapeutic COVID-19 drugs, we present an overview of the gl
    Document: The World Health Organization (WHO) has declared coronavirus disease 2019 (COVID-19) is the first pandemic caused by coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, there is no effective anti-SARS-CoV-2 drug approved worldwide for treatment of patients with COVID-19. Therapeutic options in response to the COVID-19 outbreak are urgently needed. To facilitate the better and faster development of therapeutic COVID-19 drugs, we present an overview of the global promising therapeutic drugs, including repurposing existing antiviral agents, network-based pharmacology research, antibody development and traditional Chinese medicine. Among all these drugs, we focus on the most promising drugs (such as favipiravir, tocilizumab, SARS-CoV-2 convalescent plasma, hydroxychloroquine, Lianhua Qingwen, interferon beta-1a, remdesivir, etc.) that have or will enter the final stage of human testing—phase III–IV clinical trials.

    Search related documents:
    Co phrase search for related documents
    • accessory protein and adenosine triphosphate: 1, 2
    • acid conversion and active role: 1
    • acid conversion and active role play: 1
    • acid conversion and active site: 1
    • active ingredient and acute viral infection: 1
    • active ingredient and additional research: 1, 2
    • active nucleoside triphosphate and adenosine triphosphate: 1
    • active role and acute viral infection: 1
    • active role and adenosine triphosphate: 1
    • active role and liver damage: 1
    • active site and acute viral infection: 1
    • active site and additional research: 1, 2
    • active site and adenosine triphosphate: 1, 2, 3, 4
    • activity level and actual condition: 1
    • activity level and liver damage: 1, 2
    • actual condition and liver damage: 1
    • actual experience and additional work: 1
    • acute viral infection and liver damage: 1